- Home
- FGB vs BEAT Comparison
FGB vs BEAT Comparison
Compare FGB & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGB
- BEAT
- Stock Information
- Founded
- FGB 2007
- BEAT 2015
- Country
- FGB United States
- BEAT United States
- Employees
- FGB N/A
- BEAT N/A
- Industry
- FGB Finance/Investors Services
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- FGB Finance
- BEAT Technology
- Exchange
- FGB Nasdaq
- BEAT Nasdaq
- Market Cap
- FGB 58.9M
- BEAT 59.0M
- IPO Year
- FGB N/A
- BEAT 2021
- Fundamental
- Price
- FGB $4.01
- BEAT $1.80
- Analyst Decision
- FGB
- BEAT Buy
- Analyst Count
- FGB 0
- BEAT 1
- Target Price
- FGB N/A
- BEAT $8.00
- AVG Volume (30 Days)
- FGB 53.0K
- BEAT 74.8K
- Earning Date
- FGB 01-01-0001
- BEAT 05-13-2025
- Dividend Yield
- FGB 8.92%
- BEAT N/A
- EPS Growth
- FGB N/A
- BEAT N/A
- EPS
- FGB N/A
- BEAT N/A
- Revenue
- FGB N/A
- BEAT N/A
- Revenue This Year
- FGB N/A
- BEAT N/A
- Revenue Next Year
- FGB N/A
- BEAT N/A
- P/E Ratio
- FGB N/A
- BEAT N/A
- Revenue Growth
- FGB N/A
- BEAT N/A
- 52 Week Low
- FGB $2.85
- BEAT $1.45
- 52 Week High
- FGB $3.74
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- FGB 51.99
- BEAT 56.41
- Support Level
- FGB $3.97
- BEAT $1.50
- Resistance Level
- FGB $4.11
- BEAT $1.90
- Average True Range (ATR)
- FGB 0.09
- BEAT 0.13
- MACD
- FGB 0.00
- BEAT 0.02
- Stochastic Oscillator
- FGB 25.00
- BEAT 75.00
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.